PRESS RELEASES

Date	Title
May 17, 2022	Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
May 16, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
May 5, 2022	Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
Apr 28, 2022	Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
Apr 25, 2022	Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
Apr 12, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Apr 11, 2022	Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
Apr 7, 2022	Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
Apr 4, 2022	Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
Mar 9, 2022	Ardelyx, Inc. Reports Employment Inducement Grants

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com